The analyses of the collection of human gliomas available from The Cancer Genome Atlas (TCGA) (https://tcga-data.nci.nih.gov/tcga/), which used the same DNA methylation microarray platform as that used here for our initial Sanger cell line screening, showed the presence of NSUN5 promoter CpG island methylation in 28% (190 of 681) of gliomas of different grades (Fig. 7a and Suppl. This evidence concerns the gene NSUN5 and central nervous system cancer.